Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesPrognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: A Southwest Oncology Group Study
Annals of Oncology, 11/09/09
Sweetenham JW et al. – Immune cell composition of lymph nodes did not correlate with OS in this analysis of trials in FL. The mechanism of the observed correlation between MUM-1 expression and adverse prognosis in patients receiving monoclonal antibody therapy requires confirmation.
Methods- Tissue microarrays constructed from archived tissue obtained from patients on 3 sequential Southwest Oncology Group (SWOG) trials for FL
- Trials included anthracycline-based chemotherapy
- Anti-CD20 monoclonal antibodies included for patients in latter 2 trials
- Immunohistochemistry used to study number and distribution of cells staining for forkhead box protein P3 (FOXP3) and lymphoma-associated macrophages (LAMs) and number of lymphoma cells staining for myeloma-associated antigen-1 (MUM-1)
- Cox proportional hazards regression used to evaluate association between marker expression and OS
- Number or pattern of infiltrating FOXP3 cells and LAMs did not correlate with OS in sequential SWOG studies for FL
- Presence of MUM-1 correlated with lower OS for patients who received monoclonal antibody but not for those treated with chemotherapy alone
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia
Haematologica, 12/20/09
The mitogen-activated protein kinase signaling pathways: role in megakaryocyte differentiation
Journal of Thrombosis and Haemostasis, 12/20/09
Reprogramming T Lymphocytes for Melanoma Adoptive Immunotherapy by T-Cell Receptor Gene Transfer with Lentiviral Vectors
Cancer Research, 12/20/09
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia
Haematologica, 12/20/09
Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
Journal of Clinical Oncology, 12/20/09
Cytogenetics of long-term survivors of ETV6-RUNX1 fusion positive acute lymphoblastic leukemia
Genes, Chromosomes and Cancer, 12/19/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Journal of Clinical Oncology, 12/20/09
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Journal of Clinical Oncology, 12/20/09
Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
Journal of Clinical Oncology, 12/20/09
Sponsor
Article Search
Sponsor
Sponsor